By Fineline Cube 
US-based Stryker (NYSE: SYK) announced this week that its OptaBlate Basivertebral Nerve Ablation (BVN) system has obtained 510(k) clearance from the US Food and Drug Administration (FDA). This marks a significant milestone in the company’s efforts to provide advanced solutions for vertebrogenic pain management.
OptaBlate BVN System Overview
The OptaBlate BVN system is designed for targeted, minimally-invasive procedures aimed at providing long-term relief of vertebrogenic pain. This innovative system integrates Stryker’s expertise in two core technological domains: radiofrequency ablation and vertebral intervention. By combining these advanced technologies, the OptaBlate BVN system offers a comprehensive approach to treating pain originating from the vertebrae.-Fineline Info & Tech